FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011308545> ?p ?o ?g. }

• W2011308545 abstract "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, ILIntroduction: The success of personalized medicine in oncology relies on translational research efforts to identify biomarkers that will influence clinical management. The discovery and validation of biomarkers is a concerted effort requiring an organizational framework that is often underestimated. The Quebec Clinical Research Organization in Cancer (Q-CROC) consortium is a multi-disciplinary and multi-institutional group of scientists and clinicians devoted to integrating and enhancing translational and clinical research capacity in Quebec. We describe here the organizational framework driving a multicenter, prospective study to identify biomarkers of clinical resistance to first-line therapy in metastatic colorectal cancer ([NCT00984048][1], Q-CROC-01). Results: The Q-CROC consortium has put in place an organizational infrastructure to support the activities and operations of its translational projects. We identified and addressed several critical issues during the course of the Q-CROC-01 translational project that were also common to our subsequent biomarker-driven trial in lymphoma (Q-CROC-02, [NCT01238692][2]) and breast cancer (Q-CROC-03, [NCT01276899][3]). Examples of these issues include: (i) feasibility and burden of tissue collection at participating sites, (ii) limiting pre-analytical variability in blood and tissue specimens for functional downstream applications, (iii) verification of tumor content on biopsy specimens, (iv) tracking sample flow, (v) integration of clinical data with discovery platforms, and (vi) engaging participation throughout all steps of the project. In part to address the above issues, we established five operational Cores: clinical, biobank, biospecimen processing, bioanalytical and bioinformatic. A further challenge was the integration between these Cores, who for the most part operated in silos. We observed that a critical element to unify all components of the consortium was a scientific project management team, consisting of dedicated individuals regularly interacting with each Core to ensure that objectives were aligned and deliverables were met. This academic framework for translational research may be comparable to that of multicenter clinical trials undertaken by industry, but some challenges, including financial and time constraints, data sharing and IP agreements, and engagement of its members, may be more palpable in the academic setting. Conclusion: Infrastructure science is underestimated and under-reported in translational cancer research and is crucial to the success of any large-scale biomarker discovery effort. Our experience with three multi-institutional biomarker-driven trials is that progress hinges upon the availability of an infrastructure that is not only the sum of its parts but that provides a concrete link between each component.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5534. doi:1538-7445.AM2012-5534 [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00984048&atom=%2Fcanres%2F72%2F8_Supplement%2F5534.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01238692&atom=%2Fcanres%2F72%2F8_Supplement%2F5534.atom [3]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01276899&atom=%2Fcanres%2F72%2F8_Supplement%2F5534.atom" @default.
• W2011308545 created "2016-06-24" @default.
• W2011308545 creator A5001700783 @default.
• W2011308545 creator A5002072156 @default.
• W2011308545 creator A5005764534 @default.
• W2011308545 creator A5008432805 @default.
• W2011308545 creator A5009190068 @default.
• W2011308545 creator A5010297386 @default.
• W2011308545 creator A5010372361 @default.
• W2011308545 creator A5012005454 @default.
• W2011308545 creator A5019526929 @default.
• W2011308545 creator A5022250135 @default.
• W2011308545 creator A5023267102 @default.
• W2011308545 creator A5023628228 @default.
• W2011308545 creator A5024490678 @default.
• W2011308545 creator A5024815006 @default.
• W2011308545 creator A5026360110 @default.
• W2011308545 creator A5027409786 @default.
• W2011308545 creator A5028859506 @default.
• W2011308545 creator A5029097581 @default.
• W2011308545 creator A5029580614 @default.
• W2011308545 creator A5031333036 @default.
• W2011308545 creator A5034004011 @default.
• W2011308545 creator A5037386757 @default.
• W2011308545 creator A5038842747 @default.
• W2011308545 creator A5039429688 @default.
• W2011308545 creator A5041219905 @default.
• W2011308545 creator A5041818368 @default.
• W2011308545 creator A5048013287 @default.
• W2011308545 creator A5048707534 @default.
• W2011308545 creator A5049481562 @default.
• W2011308545 creator A5050879006 @default.
• W2011308545 creator A5051029434 @default.
• W2011308545 creator A5052864271 @default.
• W2011308545 creator A5055280080 @default.
• W2011308545 creator A5056081721 @default.
• W2011308545 creator A5057513909 @default.
• W2011308545 creator A5058808748 @default.
• W2011308545 creator A5062137018 @default.
• W2011308545 creator A5063193415 @default.
• W2011308545 creator A5068296807 @default.
• W2011308545 creator A5074187114 @default.
• W2011308545 creator A5074729432 @default.
• W2011308545 creator A5076716605 @default.
• W2011308545 creator A5083346006 @default.
• W2011308545 creator A5090421334 @default.
• W2011308545 creator A5091028771 @default.
• W2011308545 creator A5091461745 @default.
• W2011308545 date "2012-04-15" @default.
• W2011308545 modified "2023-10-18" @default.
• W2011308545 title "Abstract 5534: Building the organization framework for biopsy-driven translational research: The Quebec Clinical Research Organization in Cancer (Q-CROC) experience" @default.
• W2011308545 doi "https://doi.org/10.1158/1538-7445.am2012-5534" @default.
• W2011308545 hasPublicationYear "2012" @default.
• W2011308545 type Work @default.
• W2011308545 sameAs 2011308545 @default.
• W2011308545 citedByCount "0" @default.
• W2011308545 crossrefType "proceedings-article" @default.
• W2011308545 hasAuthorship W2011308545A5001700783 @default.
• W2011308545 hasAuthorship W2011308545A5002072156 @default.
• W2011308545 hasAuthorship W2011308545A5005764534 @default.
• W2011308545 hasAuthorship W2011308545A5008432805 @default.
• W2011308545 hasAuthorship W2011308545A5009190068 @default.
• W2011308545 hasAuthorship W2011308545A5010297386 @default.
• W2011308545 hasAuthorship W2011308545A5010372361 @default.
• W2011308545 hasAuthorship W2011308545A5012005454 @default.
• W2011308545 hasAuthorship W2011308545A5019526929 @default.
• W2011308545 hasAuthorship W2011308545A5022250135 @default.
• W2011308545 hasAuthorship W2011308545A5023267102 @default.
• W2011308545 hasAuthorship W2011308545A5023628228 @default.
• W2011308545 hasAuthorship W2011308545A5024490678 @default.
• W2011308545 hasAuthorship W2011308545A5024815006 @default.
• W2011308545 hasAuthorship W2011308545A5026360110 @default.
• W2011308545 hasAuthorship W2011308545A5027409786 @default.
• W2011308545 hasAuthorship W2011308545A5028859506 @default.
• W2011308545 hasAuthorship W2011308545A5029097581 @default.
• W2011308545 hasAuthorship W2011308545A5029580614 @default.
• W2011308545 hasAuthorship W2011308545A5031333036 @default.
• W2011308545 hasAuthorship W2011308545A5034004011 @default.
• W2011308545 hasAuthorship W2011308545A5037386757 @default.
• W2011308545 hasAuthorship W2011308545A5038842747 @default.
• W2011308545 hasAuthorship W2011308545A5039429688 @default.
• W2011308545 hasAuthorship W2011308545A5041219905 @default.
• W2011308545 hasAuthorship W2011308545A5041818368 @default.
• W2011308545 hasAuthorship W2011308545A5048013287 @default.
• W2011308545 hasAuthorship W2011308545A5048707534 @default.
• W2011308545 hasAuthorship W2011308545A5049481562 @default.
• W2011308545 hasAuthorship W2011308545A5050879006 @default.
• W2011308545 hasAuthorship W2011308545A5051029434 @default.
• W2011308545 hasAuthorship W2011308545A5052864271 @default.
• W2011308545 hasAuthorship W2011308545A5055280080 @default.
• W2011308545 hasAuthorship W2011308545A5056081721 @default.
• W2011308545 hasAuthorship W2011308545A5057513909 @default.
• W2011308545 hasAuthorship W2011308545A5058808748 @default.
• W2011308545 hasAuthorship W2011308545A5062137018 @default.
• W2011308545 hasAuthorship W2011308545A5063193415 @default.
• W2011308545 hasAuthorship W2011308545A5068296807 @default.
• W2011308545 hasAuthorship W2011308545A5074187114 @default.
• W2011308545 hasAuthorship W2011308545A5074729432 @default.
• W2011308545 hasAuthorship W2011308545A5076716605 @default.
• W2011308545 hasAuthorship W2011308545A5083346006 @default.

• next